Neuroscience News and Research

RSS

Health researchers speak about PTSD in light of Remembrance Day

They've seen horrors, experienced constant threats and survived traumatic events. Canada's military personnel often come back home with memories they'd rather forget. It's not scientifically understood why some soldiers develop post-traumatic stress disorder (PTSD) while others don't. However, many veterans simply don't ask for psychological help.

6 Nov 2009

Autism Consortium holds its fourth annual symposium to update on autism

The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston.

6 Nov 2009

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

Internet stimulates and improves brain functioning for seniors: Study

A study by UCLA suggests that use of the Internet by seniors helps to "stimulate and possibly improve brain functioning." Dr. Gary Small, a professor at the Semel Institute for Neuroscience and Human Behavior at UCLA, noted "Internet searching engages complicated brain activity, which may help exercise and improve brain function."

6 Nov 2009

King Pharmaceuticals announces total revenues of $463M for the third quarter of 2009

King Pharmaceuticals, Inc. announced today that total revenues were $463 million during the third quarter ended September 30, 2009, compared to $388 million in the third quarter of 2008. The Company reported net income of $42 million and diluted earnings per share of $0.17 during the third quarter of 2009, compared to net income of $82 million and diluted earnings per share of $0.34 in the third quarter of the prior year.

5 Nov 2009

Patients with post-traumatic stress disorder can benefit from synthetic marijuana

Use of cannabinoids (marijuana) could assist in the treatment of post-traumatic stress disorder patients. This is exposed in a recent study carried out at the Learning and Memory Lab in the University of Haifa's Department of Psychology.

5 Nov 2009

People with MS who relapse within first five years of onset have more severe disability: Study

People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.

5 Nov 2009

USPTO issues Notice of Allowance for Transcept Pharmaceuticals' Intermezzo

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.

4 Nov 2009

Comparative study reveals similar brain networks in human and monkey brains

A study published this week in PNAS provides a comprehensive comparative functional anatomy study in human and monkey brains which reveals highly similar brain networks preserved across evolution.

4 Nov 2009

International Omega-3 Awareness Day to educate public about proven health benefits of omega-3

Scientific evidence of the health benefits of omega-3's are now so firmly established that omega-3 expert Carol A. Locke, MD, with a team of world-renowned doctors, has spearheaded the first ever International Omega-3 Awareness Day on March 3rd, 2010. Learn more at www.Omega3Day.com.

4 Nov 2009

Cannabinoids play an important role in stress-related disorders: Study

Use of cannabinoids (marijuana) could assist in the treatment of post-traumatic stress disorder patients. This is exposed in a new study carried out at the Learning and Memory Lab in the University of Haifa's Department of Psychology. The study, carried out by research student Eti Ganon-Elazar under the supervision of Dr. Irit Akirav, was published in the prestigious Journal of Neuroscience.

4 Nov 2009

Inner sense of cardiovascular state relies on two independent pathways, shows study

A new study suggests that the inner sense of our cardiovascular state, our "interoceptive awareness" of the heart pounding, relies on two independent pathways, contrary to what had been asserted by prominent researchers.

4 Nov 2009

Program to address neuroscientific progress in pain management

On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture “From a Neuroscience of Pain to a Neuroethics of Care” by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.

4 Nov 2009

Study: Estrogen replacement may help protect brain damage

Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

NuPathe and SurModics sign a drug delivery technology license agreement

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced today that the companies have entered into a license agreement for drug delivery technology.

3 Nov 2009

Neuroscience News and Research

Health researchers speak about PTSD in light of Remembrance Day

Autism Consortium holds its fourth annual symposium to update on autism

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Internet stimulates and improves brain functioning for seniors: Study

King Pharmaceuticals announces total revenues of $463M for the third quarter of 2009

Patients with post-traumatic stress disorder can benefit from synthetic marijuana

People with MS who relapse within first five years of onset have more severe disability: Study

USPTO issues Notice of Allowance for Transcept Pharmaceuticals' Intermezzo

Comparative study reveals similar brain networks in human and monkey brains

International Omega-3 Awareness Day to educate public about proven health benefits of omega-3

Cannabinoids play an important role in stress-related disorders: Study

Inner sense of cardiovascular state relies on two independent pathways, shows study

Program to address neuroscientific progress in pain management

Study: Estrogen replacement may help protect brain damage

NIH awards $4 million research grant to AllTranz

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Phase 1 study of STX107 for Fragile X syndrome begins

NuPathe and SurModics sign a drug delivery technology license agreement

Neuroscience - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News